TianYu Bio-Technology(603717)

Search documents
天域生物(603717) - 上海市锦天城律师事务所关于天域生物科技股份有限公司2025年第二次临时股东大会的法律意见书
2025-07-16 09:30
上海市锦天城律师事务所 关于天域生物科技股份有限公司 2025年第二次临时股东大会的 法律意见书 锦 天 域 律师事务 所 ALLBRIGHT LAW OFFICES 地址:上海市浦东新区银城中路 501 号上海中心 11、12 层 电话: 021-20511000 传真: 021-20511999 邮编: 200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于天域生物科技股份有限公司 2025年第二次临时股东大会的法律意见书 致:天域生物科技股份有限公司 上海市锦天城律师事务所(以下简称"本所")接受天域生物科技股份有限 公司(以下简称"公司")委托,就公司召开 2025年第二次临时股东大会(以 下简称"本次股东大会")的有关事宜,根据《中华人民共和国公司法》(以下 简称"《公司法》")《上市公司股东会规则》等法律、法规和其他规范性文件 以及《天域生物科技股份有限公司章程》(以下简称"《公司章程》")的有关 规定,出具本法律意见书。 为出具本法律意见书,本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定,严格履行 了法定职责, ...
天域生物(603717) - 2025年第二次临时股东大会决议公告
2025-07-16 09:30
证券代码:603717 证券简称:天域生物 公告编号:2025-052 天域生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 本次会议是否有否决议案:无 一、 会议召开和出席情况 (一)股东大会召开的时间:2025 年 7 月 16 日 (二)股东大会召开的地点:上海市杨浦区国权北路 1688 号湾谷科技园 C4 幢二层 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况: 召开和表决符合《公司法》及《公司章程》的规定。 (五)公司董事、监事和董事会秘书的出席情况 | 1、出席会议的股东和代理人人数 | 168 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数(股) | 1,770,880 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例(%) | 0.8043 | (四)表决方式是否符合《公司法》及《公司章程》的规定,大会主持情况等。 本次股东大会由公司董事会召集,公司董 ...
7月15日晚间重要公告一览
Xi Niu Cai Jing· 2025-07-15 10:11
卫星化学:上半年净利润预增31.32%-53.20% 7月15日晚,卫星化学(002648)发布2025年半年度业绩预告,公司预计上半年实现归属于上市公司股 东的净利润27亿元至31.5亿元,同比增长31.32%-53.20%;预计实现扣除非经常性损益后的净利润28.52 亿元至33.02亿元,同比增长27.65%-47.79%。 资料显示,卫星化学成立于2005年8月,主营业务是(聚)丙烯、丙烯酸及酯、乙二醇、环氧乙烷、环氧 丙烷和聚乙烯等产品的生产和销售。 所属行业:基础化工–化学原料–其他化学原料 中国核建:累计新签合同871.49亿元 7月15日晚,中国核建(601611)发布公告称,截至2025年6月,公司累计实现新签合同871.49亿元,累 计实现营业收入531.84亿元。 资料显示,中国核建成立于2010年12月,主营业务是核电工程建设及工业与民用工程建设。 所属行业:建筑装饰–基础建设–基建市政工程 资料显示,怡球资源成立于2001年3月,主营业务是利用所回收的各种废旧铝资源,进行分选、加工、 熔炼等工序,生产出再生铝合金产品。 所属行业:有色金属–工业金属–铝 光库科技:上半年净利润预增60 ...
天域生物: 2025年半年度业绩预告公告
Zheng Quan Zhi Xing· 2025-07-14 12:20
Group 1 - The company expects a net profit attributable to shareholders of 8 million to 12 million yuan for the first half of 2025, representing an increase of 177.14 thousand to 577.14 thousand yuan compared to the same period last year, with a year-on-year growth of 28.44% to 92.66% [2][3] - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -18 million and -12 million yuan, which is a decrease of 893.04 thousand to 1,493.04 thousand yuan compared to the same period last year [2][3] - The total sales revenue is projected to be 311.53 million yuan, an increase of 17.49% compared to the same period last year, driven by stable improvements in pig farming operations [2][3] Group 2 - The company reported a total profit of 14.74 million yuan and a net profit attributable to shareholders of 6.23 million yuan for the same period last year [2] - The earnings per share for the previous year was 0.0215 yuan [2] - The increase in asset disposal income is attributed to renegotiations regarding rent reductions and pig farm renovations [2]
天域生物(603717) - 2025 Q2 - 季度业绩预告
2025-07-14 11:35
[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates H1 2025 net profit attributable to shareholders to range from RMB 8 million to RMB 12 million, while net profit after non-recurring items is expected to be a loss of RMB 12 million to RMB 18 million, indicating an expanded loss H1 2025 Performance Forecast Summary | Indicator | H1 2025 Forecast | Prior Period | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | RMB 8 million to RMB 12 million | RMB 6.2286 million | +28.44% to +92.66% | | Net Profit Attributable to Parent Company Shareholders After Non-Recurring Items | RMB -18 million to RMB -12 million | RMB -3.0696 million | Loss increased by RMB 8.9304 million to RMB 14.9304 million | - This performance forecast represents preliminary calculations by the company's finance department and has not been audited by a certified public accountant[6](index=6&type=chunk) [Review of Prior Period Performance](index=2&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5) In H1 2024, the company reported net profit attributable to shareholders of RMB 6.2286 million, with a net loss of RMB 3.0696 million after non-recurring items, and basic EPS of RMB 0.0215 H1 2024 Key Financial Indicators | Indicator | H1 2024 Data | | :--- | :--- | | Total Profit | RMB 14.7447 million | | Net Profit Attributable to Parent Company Shareholders | RMB 6.2286 million | | Net Profit Attributable to Parent Company Shareholders After Non-Recurring Items | RMB -3.0696 million | | Earnings Per Share | RMB 0.0215 | [Analysis of Performance Change Reasons](index=2&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%A2%9E%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) The projected increase in net profit attributable to shareholders is primarily due to stable growth in hog sales and a one-time asset disposal gain, while the expanded loss in net profit after non-recurring items is mainly attributed to reduced interest income - Stable improvement in the operating performance of the hog farming business is a primary driver of net profit growth[9](index=9&type=chunk) Hog Sales Business Performance | Hog Sales Business | H1 2025 Data | Year-on-Year Growth | | :--- | :--- | :--- | | Sales Volume | **204,200 heads** | +21.52% | | Sales Revenue | **RMB 311.5323 million** | +17.49% | - Renegotiation of the pig farm lease contract in Caidian District, Wuhan City, resulted in reduced rent and rent exemption during the renovation period, which is expected to increase the company's asset disposal gains[9](index=9&type=chunk) - The increased loss in net profit after non-recurring items is primarily due to a decrease in interest income during the reporting period[9](index=9&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company emphasizes that this unaudited performance forecast is a preliminary calculation, and investors should refer to the officially disclosed 2025 semi-annual report for final accurate financial data - The company states that this performance forecast is preliminary and unaudited, advising investors to be aware of investment risks and rely on the final semi-annual report for definitive data[10](index=10&type=chunk)[11](index=11&type=chunk)
天域生物:预计2025年上半年净利润同比增加28.44%-92.66%
news flash· 2025-07-14 11:19
天域生物(603717)公告,预计2025年半年度实现归属于母公司所有者的净利润800万元到1200万元, 与上年同期相比,将增加177.14万元到577.14万元,同比增加28.44%到92.66%。 ...
晚间公告丨7月7日这些公告有看头





第一财经· 2025-07-07 15:32
Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets have announced significant developments, including management changes, stock trading fluctuations, and major contracts, which may present investment opportunities and risks for investors [2]. Group 1: Management Changes and Legal Issues - Scanda's chairman and general manager, Li Yuejie, along with director Zhu Chuncheng, have been subjected to criminal coercive measures due to alleged violations related to information disclosure [3]. - Longhong High-Tech is planning to acquire 100% equity of Guangxi Changke, leading to a stock suspension for up to 10 trading days [6]. Group 2: Stock Trading and Performance - New Asia Electronics reported abnormal stock trading with a cumulative price deviation exceeding 20% over three days, while confirming that its operations are normal and consistent with previously disclosed share reduction plans [5]. - ST Tiexin announced the removal of risk warnings and a name change, which will increase the trading limit from 5% to 10% [8]. Group 3: Financial Performance Forecasts - Industrial Fulian expects a net profit increase of 36.84% to 39.12% year-on-year for the first half of 2025, driven by a surge in AI-related business [18]. - Huayou Cobalt anticipates a net profit increase of 55.62% to 67.59% for the same period, benefiting from integrated operations and rising cobalt prices [19]. - Guoli Co. forecasts a staggering net profit increase of 130.91% to 158.08% for the first half of 2025, attributed to new product and market expansions [20]. - Bangji Technology expects a net profit increase of 166.77% to 200.91%, driven by increased sales from direct sales channels [21]. - Lier Chemical predicts a net profit increase of 185.24% to 196% due to rising product sales and cost reduction efforts [25]. Group 4: Major Contracts and Projects - Huadian Science and Technology signed significant contracts worth approximately RMB 25.16 billion for coal handling and transportation systems [41]. - Aerospace Engineering is the first candidate for a project with a bid of RMB 23.92 billion for a coal gasification facility [43].

天域生物(603717) - 2025年6月养殖业务主要经营数据公告
2025-07-07 10:00
2025 年 1-6 月,公司累计销售生猪 20.42 万头,同比上升 21.52%;累计销售 收入 31,153.23 万元,同比上升 17.49%。 2025 年 6 月末,公司生猪存栏 14.44 万头,同比上升 2.34%,环比上升 2.14%。 证券代码:603717 证券简称:天域生物 公告编号:2025-050 天域生物科技股份有限公司 2025 年 6 月养殖业务主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司(以下简称"公司")现将 2025 年 6 月养殖业务 主要经营数据公告如下: 一、2025 年 6 月养殖行业主要经营数据 2025 年 6 月,公司销售生猪 3.18 万头,销售收入 3,748.42 万元,环比变动分 别为 28.00%、-7.19%,同比变动分别为 61.57%、-4.33%。 1 2、基于生猪市场价格大幅波动以及公司投苗节奏变化等因素影响,未来公 司生猪销售数量和销售收入存在月度波动风险,敬请广大投资者注意投资风险。 特此公告。 天域生物 ...
天域生物科技股份有限公司关于使用自有资金支付募投项目部分款项并以募集资金等额置换的公告
Shang Hai Zheng Quan Bao· 2025-06-30 20:08
Core Viewpoint - Tianyu Biological Technology Co., Ltd. has announced the use of its own funds to pay for part of the fundraising investment project and will replace it with an equivalent amount of raised funds, ensuring the smooth implementation of the project without affecting the interests of shareholders [1][8][11]. Fundraising Basic Situation - The company raised a total of RMB 402.27 million by issuing 48.35 million shares at a price of RMB 8.32 per share, with a net amount of RMB 393.87 million after deducting issuance costs [1]. Fundraising Investment Project Situation - The company adjusted its fundraising usage plan due to the net amount being less than initially planned, with the project "Tianchang Longgang Red Cultural Tourism Scenic Area Engineering General Contracting Project" extended to be operational by December 2025 [3]. Reasons and Process for Using Own Funds - The company faced difficulties in directly using raised funds for certain payments, such as wages for migrant workers, which necessitated the use of its own funds initially, followed by a replacement with raised funds [5][6]. Impact on the Company - The decision to use self-funds for part of the project payments will not affect the normal implementation of the fundraising project and will not change the direction of the raised funds or harm the interests of shareholders [8][10]. Review Procedures and Opinions - The board of directors and the supervisory board have approved the use of self-funds and the subsequent replacement with raised funds, confirming that the decision aligns with the interests of the company and shareholders [9][10].
天域生物(603717) - 中德证券有限责任公司关于天域生物科技股份有限公司使用自有资金支付募投项目部分款项并以募集资金等额置换的核查意见
2025-06-30 10:16
中德证券有限责任公司 根据中国证券监督管理委员会出具的《关于核准天域生态环境股份有限公司 非公开发行股票的批复》(证监许可[2021]101 号),公司获准非公开发行人民币 普通股(A 股)股票 4,835 万股,每股发行价格为人民币 8.32 元,募集资金总额 为人民币 402,272,000.00 元,扣除不含税各项发行费用人民币 8,406,457.62 元, 募集资金净额为人民币 393,865,542.38 元。上述募集资金已全部到账,并经众华 会计师事务所(特殊普通合伙)进行了审验,于 2021 年 6 月 22 日出具了"众会 字(2021)第 06405 号"《验资报告》。 为规范公司募集资金管理,保护中小投资者的权益,公司已与保荐机构和存 放募集资金的商业银行签订《募集资金专户储存三方监管协议》。 关于天域生物科技股份有限公司 使用自有资金支付募投项目部分款项 并以募集资金等额置换的核查意见 中德证券有限责任公司(以下简称"保荐机构"、"中德证券")作为天域生 物科技股份有限公司(以下简称"天域生物"或"公司",曾用名"天域生态环 境股份有限公司")2020 年非公开发行股票的保荐机构,根据 ...